RecruitingPhase 4NCT05525767

Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer

Prospective, Multicenter, Single-arm Clinical Study of Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for Early or Locally Advanced HER2-negative Breast Cancer

Sponsor

Hebei Medical University Fourth Hospital

Enrollment

75 participants

Start Date

Mar 31, 2022

Study Type

INTERVENTIONAL

Conditions

Solid Tumor

Summary

This is an prospective, multicenter, single-arm clinical study.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether adding bevacizumab (a drug that blocks blood vessel growth in tumors) to standard chemotherapy before surgery improves outcomes in people with HER2-negative breast cancer. **You may be eligible if...** - You are 18 or older with HER2-negative invasive breast cancer confirmed by biopsy — this includes triple-negative breast cancer and hormone receptor-positive (ER/PR+) breast cancer - Your cancer is stage II–IIIC (locally advanced but not yet spread to distant organs) - Your blood counts, liver, kidney, and heart function are within acceptable ranges - Your heart's pumping strength (LVEF) is 55% or higher **You may NOT be eligible if...** - Your cancer has already spread to distant organs (stage IV) - You have already received any treatment for this breast cancer (chemotherapy, hormone therapy, radiation, or immunotherapy) - You are pregnant or breastfeeding - You are currently enrolled in another interventional clinical trial Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBevacizumab

All subjects enrolled will receive bevacizumab .Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.